Concord Biotech (CONCORDBIO) Stock Overview
A biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for CONCORDBIO from our risk checks.
CONCORDBIO Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Concord Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,417.60 |
| 52 Week High | ₹2,451.70 |
| 52 Week Low | ₹1,345.00 |
| Beta | 0.60 |
| 1 Month Change | -2.41% |
| 3 Month Change | -15.70% |
| 1 Year Change | -33.37% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 50.36% |
Recent News & Updates
Recent updates
Concord Biotech Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 16
With EPS Growth And More, Concord Biotech (NSE:CONCORDBIO) Makes An Interesting Case
Jul 15Market Participants Recognise Concord Biotech Limited's (NSE:CONCORDBIO) Earnings Pushing Shares 30% Higher
Jun 10Concord Biotech Limited (NSE:CONCORDBIO) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 02Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?
Apr 08What You Can Learn From Concord Biotech Limited's (NSE:CONCORDBIO) P/E After Its 27% Share Price Crash
Mar 01
Launching New Niche APIs And Commercializing Injectable Plant Will Ensure Future Success
Expansion in formulation business and niche APIs could bolster market share, particularly in oncology and anti-infectives, enhancing revenue and earnings.Earnings Miss: Here's What Concord Biotech Limited (NSE:CONCORDBIO) Analysts Are Forecasting For Next Year
Feb 16Here's Why We Think Concord Biotech (NSE:CONCORDBIO) Might Deserve Your Attention Today
Jan 06Concord Biotech Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 14Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?
Sep 15Concord Biotech Limited (NSE:CONCORDBIO) Not Lagging Market On Growth Or Pricing
Jul 23Is Concord Biotech (NSE:CONCORDBIO) Using Too Much Debt?
Feb 14Shareholder Returns
| CONCORDBIO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.7% | 0.5% | -0.5% |
| 1Y | -33.4% | -0.3% | 2.5% |
Return vs Industry: CONCORDBIO underperformed the Indian Pharmaceuticals industry which returned -0.3% over the past year.
Return vs Market: CONCORDBIO underperformed the Indian Market which returned 2.5% over the past year.
Price Volatility
| CONCORDBIO volatility | |
|---|---|
| CONCORDBIO Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.5% |
| 10% least volatile stocks in IN Market | 3.1% |
Stable Share Price: CONCORDBIO has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: CONCORDBIO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,571 | Sudhir Vaid | www.concordbiotech.com |
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment.
Concord Biotech Limited Fundamentals Summary
| CONCORDBIO fundamental statistics | |
|---|---|
| Market cap | ₹148.30b |
| Earnings (TTM) | ₹3.24b |
| Revenue (TTM) | ₹11.25b |
Is CONCORDBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CONCORDBIO income statement (TTM) | |
|---|---|
| Revenue | ₹11.25b |
| Cost of Revenue | ₹4.03b |
| Gross Profit | ₹7.22b |
| Other Expenses | ₹3.98b |
| Earnings | ₹3.24b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 30.97 |
| Gross Margin | 64.20% |
| Net Profit Margin | 28.79% |
| Debt/Equity Ratio | 0% |
How did CONCORDBIO perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/28 00:57 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Concord Biotech Limited is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Deepika Murarka | Choice Equity Broking Private Limited |